Kalaris Therapeutics (NASDAQ:KLRS) Issues Earnings Results, Beats Estimates By $0.06 EPS

Kalaris Therapeutics (NASDAQ:KLRS) announced its quarterly earnings data on Tuesday. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.52) by $0.06, FiscalAI reports.

Kalaris Therapeutics Trading Down 2.7%

KLRS traded down $0.13 during trading on Tuesday, hitting $4.60. 82,930 shares of the company’s stock traded hands, compared to its average volume of 74,745. The stock has a market capitalization of $105.75 million, a price-to-earnings ratio of -1.09 and a beta of 0.15. The company’s 50 day simple moving average is $6.89 and its two-hundred day simple moving average is $7.52. Kalaris Therapeutics has a 12-month low of $2.14 and a 12-month high of $11.88.

Analysts Set New Price Targets

KLRS has been the subject of several analyst reports. Wall Street Zen upgraded Kalaris Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, March 15th. Morgan Stanley assumed coverage on shares of Kalaris Therapeutics in a research report on Thursday, April 16th. They set an “overweight” rating and a $14.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $14.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of KLRS. OMERS ADMINISTRATION Corp purchased a new position in Kalaris Therapeutics in the 4th quarter worth about $253,000. State Street Corp boosted its holdings in shares of Kalaris Therapeutics by 12.4% during the 4th quarter. State Street Corp now owns 25,410 shares of the company’s stock valued at $214,000 after acquiring an additional 2,800 shares during the last quarter. Bridgeway Capital Management LLC bought a new stake in shares of Kalaris Therapeutics in the third quarter worth approximately $130,000. Walleye Capital LLC bought a new stake in shares of Kalaris Therapeutics in the fourth quarter worth approximately $95,000. Finally, XTX Topco Ltd purchased a new position in shares of Kalaris Therapeutics during the fourth quarter valued at approximately $92,000. 66.05% of the stock is owned by institutional investors.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.